Ethinylestradiol-levonorgestrel versus spironolactone-pioglitazone-metformin (SPIOMET) for adolescent girls with hyperinsulinemic androgen excess: effects on hepatic and visceral fat and on insulin sensitivity

Trial Profile

Ethinylestradiol-levonorgestrel versus spironolactone-pioglitazone-metformin (SPIOMET) for adolescent girls with hyperinsulinemic androgen excess: effects on hepatic and visceral fat and on insulin sensitivity

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2016

At a glance

  • Drugs Ethinylestradiol/levonorgestrel (Primary) ; Metformin (Primary) ; Pioglitazone (Primary) ; Spironolactone (Primary)
  • Indications Polycystic ovary syndrome
  • Focus Pharmacodynamics
  • Acronyms OC vs SPIOMET
  • Most Recent Events

    • 11 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 11 Dec 2015 Planned End Date changed from 10 Dec 2016 to 30 Dec 2018 as per ISRCTN: Current Controlled Trials record.
    • 11 Dec 2015 Status changed from not yet recruiting to recruiting as per ISRCTN: Current Controlled Trials record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top